All relevant data are within the paper.

Introduction {#sec001}
============

The PD-1/PD-L1 axis (Programmed death 1 or CD274/ programmed death-ligand 1) plays a crucial role in immune surveillance. PD-1 is a transmembrane protein expressed on activated T and B cells and binds to its ligands, PD-L1 or PD-L2, which are variably expressed in immune (T and B cells, dendritic cells, mast cells) and non-immune (e.g. endothelial) cells including tumour cells. The PD-1/PD-L1 axis acts as an immune checkpoint by inhibiting T-cell function leading to tumour immune escape (Reviewed in\[[@pone.0222551.ref001], [@pone.0222551.ref002]\]). Therapeutic blockage of the PD-1/PD-L1 receptor--ligand can result in durable clinical responses in lung and bladder cancer \[[@pone.0222551.ref002]--[@pone.0222551.ref006]\] but their benefit in various sarcoma subtypes remains unknown, with no phase 3 studies yet published.

The frequency of PD-L1 expression in sarcomas reported in the literature is highly variable with incidences ranging from 0% to 65%\[[@pone.0222551.ref005], [@pone.0222551.ref007]--[@pone.0222551.ref019]\]. In their analysis, some of these series have combined statistical analysis of the two molecularly characteristic groups of sarcomas, that is those associated with recurrent specific genetic events (e.g. translocations or amplification) known to drive tumorogenesis (e.g. t(X;18)(p11.2; q11.2) in synovial sarcoma) and sarcomas with complex karyotype (e.g. myxofibrosarcoma), which lack detectable recurrent gene alterations, as a single entity \[[@pone.0222551.ref020]--[@pone.0222551.ref023]\]. Such distinction is fundamental as sarcomas across the different groups and within the same group show distinct clinical behaviour.

The predictive and prognostic significance of PD-L1 expression in sarcomas has also been reviewed including its correlation with PD-1 expression, and the presence and degree of tumour-infiltrating lymphocytes (TILs) \[[@pone.0222551.ref005], [@pone.0222551.ref007]--[@pone.0222551.ref019]\].

The aims of our study were threefold. To review the incidence of PD-L1 expression in a cohort of 522 selected bone and soft tissue sarcomas from 457 patients with the commercially available and widely used PD-L1 companion kit SP263 (Ventana)\[[@pone.0222551.ref024]\]. This immunohistochemical assay in other tumour types (i.e. lung and urothelial) can identify patients more likely to benefit from treatment with anti-PD-L1 immunotherapy such as durvalumab, pembrolizumab and nivolumab. Only few studies using the clone SP263 have been published in sarcoma patients \[[@pone.0222551.ref010], [@pone.0222551.ref018]\]. A second aim was to review the level of concordance in PD-L1 expression in matched sarcoma samples from primary tumour and its recurrence and/or metastasis (or metachronous recurrent/metastatic episodes). The purpose was to identify whether changes in PD-L1 expression occur during the evolution of more aggressive sarcomas and if so, these may impact treatment of refractory advanced disease. Lastly, we correlated PD-L1 expression with the presence and degree of TILs identified on H&E sections for a subset of cases. The significance of TILs identified on routine H&E sections in sarcomas has not been widely investigated.

Materials and methods {#sec002}
=====================

This study was approved by the Northern Sydney Local Health District (NSLHD) Human Research Ethics Committee (HREC) reference 1312-417M. Consent was not obtained as this is a retrospective cohort of de-identified archival tissue samples. A retrospecitve database search was performed on the archives of Douglass Hanly Moir (DHM) Pathology laboratory in a 10-year (2008--2018) period of time to identify a cohort of selected bone and soft tissue sarcomas. Our cohort was limited to resection specimens to ensure tissue availability and viable representative tumour. Selection of sarcoma subytpes was based on the most prevalent soft tissue sarcomas identified in our laboratory with rare sarcomas excluded to ensure statistical power in the analysis. All our cases have been previously diagnosed by pathologists with sarcoma expertise following standardised diagnostic criteria\[[@pone.0222551.ref020]\], which included the used of FISH probes (Break-apart: SS18, EWSR1, FOXO1, DDIT3, FUS; and enumeration: MDM2) when required for tumour classification. As this is a de-identified cohort, follow-up is not available. Ewing sarcomas were the only primary bone tumours included in this cohort, all of which had an associated soft tissue component not requiring prior decalcification. Only formalin-fixed paraffin-embedded (FFPE) tissue blocks with adequate viable tumour from resection specimens were selected for construction of tissue microarrays (TMAs). Replicate tissue microarray (TMA) cores were taken from each sample (2x1 mm cores). For PD-L1 IHC, paraffin blocks were sectioned at 4 μm on to Superfrost Plus slides and stained with the Ventana PD-L1 SP263 rabbit monoclonal primary antibody (Assay v1.00.0001), using the VENTANA OptiView DAB IHC Detection Kit and the BenchMark ULTRA platform. IHC was performed on TMAs for the entire cohort and on full sections for a subset of cases (n = 23). Positive (normal placenta as described \[[@pone.0222551.ref025]\] and negative controls were included in each run. Positive PD-L1 expression in the tumour cells was scored semiquantitatively as 0--3+, based on weak, moderate and strong membranous staining, respectively and the percentage of tumour cells expressing the protein was recorded. Following standard guidelines as per lung for the clone SP263\[[@pone.0222551.ref024]\], PD-L1 expression was regarded as positive if complete or incomplete membranous expression was present in ≥1% of the tumour cells regardless the intensity. PD-L1 expression on immune cells (lymphocytes and/or plasma cells) was also recorded when identified. Although we aimed to score PD-L1 on 100 viable tumour cells, this was not achievable for sarcomas with low cellularity on TMAs. Nevertheless, standardised criteria for PD-L1 scoring, including the minimal number of cells for PD-L1 expression, in the context of sarcoma samples has not been universally established.

Evaluation of TILs was performed on 2 to 3 representative full H&E sections (4 microns in thickness) per each case only for the sarcoma subtypes with the largest number of cases (UPS, MFS and LMS) and for the metastatic/recurrent samples (Met/Rec cohort: n = 306). TILs were scored following the recommendations by the International TILs Working Group for breast cancer\[[@pone.0222551.ref031]\]. Briefly, the intratumoural area occupied by stromal TILs was expressed as a percentage. TILs were assessed in areas away from necrosis. Tertiary lymphoid structures and other inflammatory cells (i.e. neutrophils and histiocytes) were excluded. The level of TILS was regarded as nil (0%), minimal (1--10%), intermediate (\>10% and \<50%) and high (\>50%). These cut-offs were selected following the groups A-C of Salgado et al \[[@pone.0222551.ref026]--[@pone.0222551.ref027]\], with the exception that for this study, absent TILs (0%) was differentially recorded from mild TILs (1--10%). A limitation of applying this system to sarcomas is that, contrary to breast cancer, the tumour boundary in a proportion of sarcoma subtypes is not well defined.

For statistical analysis the Fisher exact test for a 2 x 2 contingency table and the Mann Whitney test were used to establish significant correlations between PD-L1 and TILs with significance determined at P value: \<0.05. An online calculator was used for the analysis: <https://www.socscistatistics.com/tests/fisher/default2.aspx> and <https://www.socscistatistics.com/tests/mannwhitney/>.

Results {#sec003}
=======

Overall cohort {#sec004}
--------------

The entire cohort assessed for PD-L1 IHC on TMAs comprised 522 samples from 457 patients. These included primary uterine and soft tissue leiomyosarcomas (LMS n = 116), atypical lipomatous tumours/well- differentiated liposarcomas (ALT/WD-LPS, n = 95), myxofibrosarcomas (MFSs, n = 97), undifferentiated pleomorphic sarcomas (UPS, n = 67), dedifferentiated liposarcomas (DD-LPS, n = 37), myxoid liposarcomas (ML, n = 27), rhabdomyosarcomas (RMS, n = 24: 9 pleomorphic, 7 embryonal, 4 alveolar and 3 spindle cell/sclerosing), synovial sarcomas (SS, n = 17), angiosarcomas (n = 17), Ewing sarcomas (ES, n = 14) and pleomorphic liposarcomas (n = 11). From this cohort, 63 samples were derived from recurrent/metastatic specimens (plus residual disease for a few of these cases, [Table 1](#pone.0222551.t001){ref-type="table"}) referred to as Rec/met cohort, from 46 patients.

10.1371/journal.pone.0222551.t001

###### Matched sarcoma samples from 46 pateints (Met/Rec cohort) with results for PD-L1 IHC and tumour-infiltrating lymphocytes (TILs).

![](pone.0222551.t001){#pone.0222551.t001g}

  Case No.   Label ID.   Patient\'s age   Diagnosis                                                    Site              Sample type   Year of Dx.   PD-L1 IHC %   TILs
  ---------- ----------- ---------------- ------------------------------------------------------------ ----------------- ------------- ------------- ------------- ----------------
  1          MFS-46      80               Myxofibrosarcoma, Gde 3, 45mm                                Calf              Primary       14            0             High
             MFS-09                       Calf                                                         Rec               16            0             No TILs       
  2          MFS-92      65               Myxofibrosarcoma, Gde 3, 115 mm                              Buttock           Primary       11            \*5%          No TILs
             MFS-71                       Thigh                                                        Rec 1             12            1%            No TILs       
             MFS-72                                                                                    Thigh             Rec 2         12            \*70%         No TILs
  3          MFS-77      76               Myxofibrosarcoma, Gde 3, 38mm, post-irradiation              Tibia             Primary       12            \*1%          No TILS
             MFS-70                       Tibia                                                        Rec 1             13            5%            No TILS       
             MFS-31                                                                                    Leg               Rec 2         13            \*5%          No TILS
             MFS-29                                                                                    Shin              Residual      13            1%            Moderate
             MFS-38                                                                                    Shin              Rec 3         14            \*10%         No TILS
  4          MFS-65      48               Myxofibrosarcoma, Gde 3, 35 mm                               Thigh             Primary       16            0             No TILS
             MFS-64                       Thigh                                                        Residual          16            0             No TILS       
             MFS-52                                                                                    Thigh             Rec           17            0             No TILS
  5          MFS-26      65               Myxofibrosarcoma, Gde 3                                      Ulna              Rec 1         10            \*1%          Moderate, het
             MFS-74                       20mm, post-irradiation                                       Forearm           Rec 2         12            \*\<1%        No TILs
  6          MFS-17      68               Myxofibrosarcoma, Gde 3, 22m                                 Arm               Rec 1         09            0             Moderate
             MFS-22                       Arm                                                          Rec 2             10            0             High          
  7          MFS-16      79               Myxofibrosarcoma Gde 2, 40 mm; post-irradiation              Calf              Rec 1         09            \*5%          Moderate, het
             MFS-35                       Calf                                                         Rec 2             13            0             No TILs       
             MFS-33                                                                                    Calf              Residual      13            1%            No TILs
             MFS-11                                                                                    Calf              Rec 3         14            \*1%          No TILs
  8          MFS-43      90               Myxofibrosarcoma, Gde 3, 54 mm                               Thigh             Rec 1         15            \*1%          Milderate, het
             MFS-60                       Thigh                                                        Rec 2             16            \*5%          No TILs       
  9          MFS-84      60               Myxofibrosarcoma, grade 3, 85 mm                             Buttock           Primary       13            \*1%          No TILs
             MFS-47                       Brain                                                        Met               14            \*1%          No TILs       
  10         MFS-80      67               Myxofibrosarcoma, Gde 2, 130mm                               Forearm           Primary       13            0             Mild
             MFS-02A                      Forearm                                                      Rec               15            0             Mild          
  11         MFS-69      83               Myxofibrosarcoma, Gde 1--45mm                                Leg               Rec 1         13            0             No TILs
             MFS-42                       Leg                                                          Rec 2             15            0             No TILs       
             MFS-63                                                                                    Leg               Rec 3         16            0             No TILs
  12         MFS-76      65               Myxofibrosarcoma, Gde 2, 33m                                 Thigh             Primary       11            0             No TILS
             MFS-07                       Thigh                                                        Residual          11            0             No TILS       
  13         MFS-85      65               Myxofibrosarcoma, Gde 2, 20mm                                Knee              Primary       11            0             No TILs
             MFS-90                       Knee                                                         Rec               11            0             No TILs       
  14         MFS-61      64               Myxofibrosarcoma, Gde 2, 60 mm                               Arm               Primary       16            0             Moderate, het
             MFS-62                       Arm                                                          Residual          16            0             Moderate      
  15         MFS-41      93               Myxofibrosarcoma, Gde 2, 155 mm                              Leg               Primary       14            0             No TILs
             MFS-48                       Leg                                                          Residual          14            0             No TILs       
             MFS-45                                                                                    Leg               Rec           14            0             No TILs
  16         MFS-55      84               Myxofibrosarcoma, Gde 2, 25mm                                Back              Primary       16            0             Mild
             MFS-56                       Back                                                         Residual          16            0             Mild          
  17         MFS-73      68               Myxofibrosarcoma, Gde 3, 90 mm                               Arm               Primary       12            0             No TILs
             MPNST1                       Arm                                                          Rec               13            0             No TILs       
  18         UPS-17      66               UPS, Gde 3, 18 mm                                            External canal    Primary       16            0             No TILs
             UPS-15                                                                                    External canal    Residual      16            0             Moderate, het
             UPS-52                                                                                    Parotid           Rec           17            0             No TILs
  19         UPS-04      40               UPS, Gde 3, 18 mm                                            Lung              Mets 1        15            0             High, het
             UPS-14                                                                                    Lung              Mets 2        16            0             No TILs
  20         UPS-40      77               UPS grade 3, 40mm                                            Buttock           Primary       14            0             No TILs
             UPS-49                                                                                    Buttock           Rec           15            0             No TILs
  21         UPS-62      74               UPS, Gde 3 67 mm                                             Groin             Rec 1         13            100%          No TILs
             UPS-61                                                                                    Groin             Rec 2         13            100%          No TILs
  22         UPS-44      61               UPS Grade 3, 50 mm, postradiotherapy                         Forearm           Primary       14            0             High
             UPS-16                       Forearm                                                      Rec               16            0             High          
  23         LM028       64               Epithelioid leiomyosarcoma, 95mm                             Uterus            Primary       12            0             No TILs
             LM024                        Vagina                                                       Mets              13            0             No TILs       
  24         LM015       60               Log-grade leiomyosarcoma, 124 mm                             Colon             Mets 1        12            0             No TILs
             LM119                        Colon                                                        Mets 2            14            0             No TILs       
             LM080                        Colon/bladder                                                Mets 3            16            0             No TILs       
  25         LM099       48               Leiomyosarcoma (Hx primary uterine) high grade, 24 mm        Lung              Mets 1        17            \*10%         High
             LM100                        Lung                                                         Mets 2            17            \*5%          High          
  26         LM020       56               Leiomyosarcoma, high gde, 190mm                              Uterus            Primary       13            \*1%          No TILs
             LM117                        Lung                                                         Mets              14            \*90%         No TILs       
  27         LM120       61               Pleomorphic leiomyosarcoma, high gde, 50 mm                  Abdomen           Primary       14            0             No TILs
             LM106                        Lung                                                         Mets              17            0             No TILs       
  28         LM062       76               High grade leiomyosarcoma, 70 mm                             Thigh             Primary       08            0             No TILs
             LM056                        Thigh                                                        Rec               09            0             No TILs       
  29         LM103       44               Leiomyosarcoma (Hx primary uterine), high gde, 108 mm        Pelvis            Rec           17            \*1%          High
             LM104                        Rectum                                                       Mets              17            \*5%          High          
  30         LM046       64               Low gde epitheliod leiomysarcoma, 15mm                       Uterus            Primary       10            0             No TILs
             LM030                        Omentum                                                      Mets              11            0             No TILs       
  31         LM051       32               Leiomyosarcoma, low grade, 124 mm                            Uterus            Primary       10            0             Mild
             LM116                        Lung                                                         Mets              15            0             No TILs       
  32         LM019       43               Leiomyosarcoma, primary, 110mm, gde 2                        Kidney            Primary       13            \*5%          No TILs
             LM118                        Omentum                                                      Mets              14            \*1%          No TILs       
  33         LM078       50               Metastatic leiomyosarcoma (Hx primary uterine)               Lung              Mets 1        16            0             No TILs
             LM079                        Lung                                                         Mets 2            16            0             No TILs       
             LM085                        Lung                                                         Mets 3            17            0             No TILs       
  34         ML03        53               Myxoid liposarcoma, 90 mm (poorly diff areas 5%)             Popliteal fossa   Primary       15            0             No TILs
             ML15                         Thigh                                                        Rec               16            0             No TILs       
  35         ML05        54               Myxoid liposarcoma, 130 mm, low grade                        Leg               Primary       14            0             No TILs
             ML16                         Lung                                                         Mets              16            0             No TILs       
  36         PLE-1       81               Pleomoprhic liposarcoma, Gde 3, 70 mm                        Arm               Primary       15            0             No TILs
             PLE-7                        Arm                                                          Rec               18            0             No TILs       
  37         PLE-3       51               Pleomoprhic liposarcoma, post-irradiation, gde 1, 20 mm      Deltoid           Rec 1         13            0             No TILs
             PLE-5                        Deltoid                                                      Rec 2             14            0             Moderate      
  38         DD-LP28     64               Dedifferentiated liposarcoma, High gde, 225 mm               Small bowel       Rec 1         8             0             Mild
             DD-LP26                      Retroperitoneum                                              Rec 2             9             0             No TILs       
  39         AS-14       75               Angiosarcoma, low and high grade, 325mm                      Breast            Primary       15            0             No TILs
             AS-15                        Chest wall                                                   Rec               15            0             No TILs       
  40         AS-11       47               Angiosarcoma, low grade, 50 mm                               Atrium            Primary       14            0             No TILs
             AS-01                        Atrium                                                       Rec               15            0             No TILs       
  41         AS-08       79               Angiosarcoma, high grade, 55m. Previous AS, 10 years prior   Vagina            Mets 1        12            0             No TILs
             AS-09                        Gingiva                                                      Mets 2            12            0             No TILs       
  42         RMS-01      57               Pleomoprhic rhabdomyosarcoma, 30 mm                          Spermatic cord    Primary       16            \*40%         High
             RMS-08                       Brain                                                        Mets              18            \*80%         No TILs       
  43         RMS-17      17               Embryonal rhabdomyosarcoma, 65 mm, FOXO1-                    Paratesticular    Primary       14            0             No TILs
             RMS-18                       Pelvic LN                                                    Mets              14            0             No TILs       
  44         SS1-B       31               Synovial sarcoma, 150 mm, SS18+                              Femur             Primary       12            0             No TILs
             SS1-C                        Lung                                                         Mets 1            13            0             No TILs       
             SS1-D                        Lung                                                         Mets 2            13            0             No TILs       
             SS1-E                        Thgh                                                         Rec               14            0             No TILs       
             SS1-F                        Lung                                                         Mets 3            15            0             No TILs       
             SS1-G                        Lung                                                         Mets 4            15            0             No TILs       
  45         SS7-A       70               Synovial sarcoma, 55mm, SS18+                                Foot              Primary       17            0             No TILs
             SS7-B                        Leg                                                          Rec               17            0             No TILs       
  46         RC-12       30               Ewing sarcoma, post chemotherapy, 80 mm, EWSR1+              Rib               Rec 1         14            0             No TILs
             RC-02                        Vertebra                                                     Rec 2             17            0             No TILs       
             RC-01                        Lung                                                         Mets              18            0             No TILs       

Results of PD-L1 IHC are displayed as scored on tissue microarrays (TMAs) when fully concordant. Discrodant PD-L1 expression is displayed as final scoring performed on full sections (marked with an asterisk). UPS, Undifferentiated pleomorphic sarcoma; Gde, FNLCC Grade (Fédération Nationale des Centres de Lutte Contre Le Cancer); Rec, Recurrence; Mets, Metastasis; TILs, Tumour-infiltrating lymphocytes.

In the overall cohort, PD-L1 positive expression (≥1%) was identified in 31% UPSs (21/67), 29% angiosarcomas (5/17), 26% RMSs (6/24, most of which were of the pleomorphic subtype), 18% MFSs (17/97), 11% LMSs (13/116) and 10% DD-LPS (4/37). PD-L1 was negative (\<1%) in all ALT/WDL (n = 95), myxoid liposarcomas (n = 27), synovial sarcomas (n = 17), pleomorphic liposarcomas (n = 11) and Ewing sarcomas (n = 15; [Fig 1](#pone.0222551.g001){ref-type="fig"}). When identified, PD-L1 staining was limited to tumour cells with no definitive epression present in immune cells. It is possible that for cases with strong tumour expression, this obscured expression in the immune cells. As previoulsy described, PD-L1 expression was seen in macrophages and endothelial cells but this was inconsistent in these cell types across the samples. Both complete and incomplete membranous expression pattern was identified and the intensity of the stain was highly variable ([Fig 2A, 2B, 2C, 2D and 2E](#pone.0222551.g002){ref-type="fig"}). Protein expression was overall concordant in replicate cores ([Fig 2F](#pone.0222551.g002){ref-type="fig"}).

![Prevalence of PD-L1 expression in 522 selected sarcoma samples assessed on tissue microarrays (TMAs).\
The horizontal axis reflects the overall frequency of sarcoma subtypes displaying any PD-L1 expression (\>1%) using the S263 clone. The vertical axis indicates the sarcoma subtype. LPS: Liposarcoma; ALT/WD: Atypical lipomatous tumour/well differentiated liposarcoma.](pone.0222551.g001){#pone.0222551.g001}

![Strong membranous expression for PD-L1 idenified in leiomyosarcoma (LM-75), undifferentiated pleomorphic sarcomas (B,C: UPS-67 & UPS-11, respectively) and metastatic angiosarcoma (D, AS-2).\
Focal heterogenous expression for PD-L1 in leiomyosarcoma (E, LM99). Concordant expression for PD-L1 in replicate cores was identified (e.g. 1F; UPS-21). Primary and recurrent UPS (UPS-61 and UPS-62: G & H) demonstrating concordant strong expression of PD-L1 in 100% of the tumour cells in both, the primary lesion and its recurence (TMA cores). Images taken at 2x -- 40x magnification and stained with the PD-L1 SP263 clone, Ventana.](pone.0222551.g002){#pone.0222551.g002}

Rec/Met cohort {#sec005}
--------------

This includes paired samples from the following types: MFS (n = 17), UPS (n = 5), LMS (n = 11), RMS (n = 2), ML (n = 2), pleomorphic LPS (n = 2), angiosarcomas (n = 3), SS (n = 2), ES (n = 1) and DD-LPS (n = 1; [Table 1](#pone.0222551.t001){ref-type="table"}). The median interval between acquisitions of paired lesions was variable (Range 0--6 years, [Table 1](#pone.0222551.t001){ref-type="table"}). All paired samples including residual disease and those occurring \<1 year apart were derived from independent surgical procedures ([Table 1](#pone.0222551.t001){ref-type="table"}). These were included to assess for intra-tumour heterogeneity. Overall, PD-L1 was concordant amongst matched / paired samples for 79% of the cases when assessed on TMAs (37 of 46 patients). For the remaining 21% with discordant PD-L1 on TMAs, IHC was performed on full sections, which increased the level of concordance from 79% to 81%. A few of these cases were initially scored as negative on TMAs but on full sections, unequivocal PD-L1 stain was identified in \>1% of the cells. Except for one, all cases lacked PD-L1 expression. Hence, these were negatively concordant (0% PD-L1 expression). The remaining case (UPS) displayed 100% expression concordantly in the primary and recurrent sample ([Fig 2G and 2H](#pone.0222551.g002){ref-type="fig"}). As this recurrence was identified soon after the resection of the primary tumour, it may represent residual disease.

Nineteen per cent of matched samples (9 of 47 patients) displayed true differences in the proportion of cells expressing PD-L1 in the primary tumour when compared to its corresponding metastasis / recurrence or between metachronous metastases / recurrent episodes. These include samples from 4 patients with MFS, 4 with LMS and 1 with pleomorphic RMS. In these samples, the percentage of PD-L1+ cells increased in the metastatic/recurrent site compared to the primary tumour in 6 of 9 cases (67%), from which 3 cases had only a modest increase (i.e. 1% to 5 or to 10%; [Table 1](#pone.0222551.t001){ref-type="table"}) but a dramatic increase was identified in the 3 remaining cases ([Fig 3](#pone.0222551.g003){ref-type="fig"}). These included a uterine leiomyosarcoma with original PD-L1 expression of 1%, which increased to 90% in its lung metastasis ([Fig 3A, 3B, 3C and 3D](#pone.0222551.g003){ref-type="fig"}), a pleomorphic rhabdomyosarcoma from the spermatic cord with increase from 40% to 80% in the brain metastasis ([Fig 3I, 3J, 3K and 3L](#pone.0222551.g003){ref-type="fig"}) and a high-grade MFS with increase from 5% to 70% in the recurrence ([Fig 3E, 3G and 3H](#pone.0222551.g003){ref-type="fig"}). Interestingly, for this MFS case, gain in PD-L1 was identified in the second recurrence (Rec 2) with the first recurrence (Rec 1) only showing 1% expression ([Table 1](#pone.0222551.t001){ref-type="table"}). PD-L1 was negative in all paired samples from angiosarcomas, myxoid liposarcomas, synovial sarcomas, pleomorphic liposarcomas and Ewing sarcomas.

![**Matched samples (A-D, E-H and I-L, respectively).** Primary uterine leiomyosarcoma diagnosed in 2013 (A, LM20) showing 1% weak expression for PD-L1 in the primary tumour (B). Lung metastasis of this tumour presented one year after the primary diagnosis (C; LM117), displaying strong PD-L1 expression in 90% of the tumour cells (D). High-grade myxofibrosarcoma (E, MFS-92) with weak PD-L1 expression in 5% of the cells (F). Recurrence one year later (G; MFS-72) demonstrated moderate to strong PD-L1 expression in 70% of the tumour cells (H). Primary rhabdomyosarcoma (I; RMS-1) with 40% heterogeneous expression for PD-L1 in the original tumour (J), which increased to 80% in the brain metastasis (K-L). In this case it can also be noted the presence of tumour-infiltrating lymphocytes (TILs) in the primary tumour (1I) but not in the brain metastasis (1K). Sections stained with Haematoxylin and Eosin (A,C,E,G,I,K) or with the PD-L1 SP263 clone, Ventana (B, D, F, H, J, L). Images taken at 10X-40X magnification.](pone.0222551.g003){#pone.0222551.g003}

TIL correlations {#sec006}
----------------

Correlation between PD-L1 expression and the presence and degree of TILs was investigated on full H&E sections exclusively on the sarcoma subtypes with the highest number of cases (MFS, UPS and LMS) and for the Mets/Rec cohort ([Table 1](#pone.0222551.t001){ref-type="table"}). MFSs and UPSs were combined for the analysis as it has been shown that these appear to represent one single biological entity within a phenotypic spectrum\[[@pone.0222551.ref021]\]. Concordant TIL and PD-L1 expression was available for 158 UPS/MFS, which showed TILs in 41% of all cases (n = 64) with 17%, 17% and 8% showing minimal, intermediate and high TILs ([Fig 4](#pone.0222551.g004){ref-type="fig"}), respectively. No association was identified with overall TIL levels and PD-L1 expression (P value 0.06 and Z-score -1.8; Mann Whitney test). To investigate further any possible correlation, TIL groups were dichotomised as cases with absent-to-minimal (\<10%) TILs vs. those with moderate-to-marked TILs (\>10%). UPS/MFSs with minimal-to-absent TILs expressed PD-L1 in 22% of cases (n = 26) and those with moderate-to-marked TILs expressed PD-L1 in 31% ([Fig 5A](#pone.0222551.g005){ref-type="fig"}). This was once again, not statistically significant (P = 0.28, Fisher's exact test).

![The images show examples of degree of TIL infiltrate classified as nil (0%, not shown), minimal (1--10%, A), intermediate (\>10% and \<50%, B) and high (\>50%, C).](pone.0222551.g004){#pone.0222551.g004}

![Prevalence of PD-L1 expression (\>1%; S263 clone) assessed on full tissue sections in a combined cohort (n = 158) of myxofibrosarcomas (MFS) and undifferentiated pleomorphic sarcomas (UPS) stratified according to the degree of tumour-infiltrating lymphocytes (TILs).\
PD-L1 expression was correlated with absent-to-low TILs (0--10%) vs. \>10% TILs. The vertical axis indicates the percentage of MFS/UPS samples (A). Prevalence of PD-L1 expression (\>1%; S263 clone) assessed on full tissue sections in a cohort of leiomyosarcomas (n = 116) stratified according to the degree of tumour-infiltrating lymphocytes (TILs). PD-L1 expression was correlated with absent-to-low TILs (0--10%) vs. \>10% TILs. The vertical axis indicates the percentage of leiomyosarcoma samples (B). Fig 5 footnote: P value calculated using Fisher's exact test.](pone.0222551.g005){#pone.0222551.g005}

For the leiomyosarcoma group (n = 116), TILs were rare, overall with 83% (n = 96) of all cases showing complete absence of TILs and with the remaining 17% having any degree of TILs (8%, 4% and 6% with minimal, intermediate and high TILs, respectively). Once again, no significant correlation was identified between overall PD-L1 expression and presence or absence of TILs in LMSs (P = 0.5; Z-score 0.66, Mann Whitney test). When the cases were dichotomised, it was observed that PD-L1 expression was present in 5% (5 of 105) of cases with minimal-to-absent TILs vs. 72% (8 of 11) in those LMS with moderate-to-marked TILs (8 of 11: 72%; \<0.0001, Fisher's exact test; [Fig 5B](#pone.0222551.g005){ref-type="fig"}).

In the Met/Rec cohort, no correlation was identified between PD-L1 expression and TILs including those cases associated with apparent gain of PD-L1 in the metastatic or recurrent deposit ([Table 1](#pone.0222551.t001){ref-type="table"}). An inverse correlation was identified in one of the three cases (pleomorphic RMS), as this showed absent TILs in the brain metastasis but high expression in the primary tumour, whereas PD-L1 expression was higher in the metastasis compared to the primary tumour (80% vs. 40%, respectively; [Fig 3I, 3J, 3K and 3L](#pone.0222551.g003){ref-type="fig"}). The other paired cases showed no TILs at initial presentation and remained absent in the metastatic/recurrent disease ([Table 1](#pone.0222551.t001){ref-type="table"}). Lastly, in this Met/Rec cohort, changes in the histomorphological features were also assessed between primary tumours and their matched recurrent/metastatic samples on full H&E sections to determine whether gain in PD-L1 in the metastatic/recurrent site was associated with changes in the morphology of the primary tumour. Although some samples showed changes, a significant trend was not observed.

Discussion {#sec007}
==========

There are several well-described factors which account for the variability in the reported expression of PD-L1 in lung adenocarcinomas and sarcomas \[[@pone.0222551.ref001], [@pone.0222551.ref018], [@pone.0222551.ref028]--[@pone.0222551.ref032]\], making comparisons of the literature challenging. One of these variables is the use of over 10 commercial and non-commercial PD-L1 antibodies including SP263 and SP142 (Ventana Medical Systems), E1L3N (Cell Signalling Technology), 22C3 (PharmDx kit, Agilent Technologies), 28--8 (PharmDx kit), 5H1 (L. Chen, John Hopkins University), \#ab58810 and EPR1161 (Abcam) and \#SAB2900365 (Sigma-Aldrich). Clones differ in the binding site to the PD-L1 protein: extracellular (28--8 and 22C3, SP263 and E1) vs. cytoplasmic (SP142 and E1L3N) (Reviewed in\[[@pone.0222551.ref001]\]) with further technical differences regarding antigen retrieval conditions, staining platforms and differential binding properties according to cell types (i.e. epithelial vs. immune). The use of inconsistent cut-offs is also a significant contributing factor to discordant PD-L1 immunohistochemical expression, and it has been shown that by adjusting predefined cut-offs this can lead to misclassification of PD-L1 status in tumour samples \[[@pone.0222551.ref030]\]. Finally, biological reasons also contribute to the lack of uniformity in PD-L1 expression. For instance, PD-L1 can be constitutive or inducible in response to IFN-γ released by effector T cells. Inducible PD-L1 can be affected by tumour location and prior therapy (Reviewed in\[[@pone.0222551.ref001]\]) including radiotherapy \[[@pone.0222551.ref033]\]. At the current time, there is not enough literature to address the dynamics of inducible PD-L1, as a result of therapy but if such changes occur, these may potentially provide therapeutic avenues to patients who may not initially be suitable for anti-PD-L1 therapy.

Although providing an average incidence of PD-L1 expression in our combined sarcoma cohort is not biologically relevant, in view of the different molecular signature of the different subytpes of soft tissue sarcomas\[[@pone.0222551.ref020], [@pone.0222551.ref023]\], PD-L1 was present in 13% of all cases in which was the protein essentially only identified in tumour cells and not in immune cells when assessed primarily on TMAs. Our study shows relatively concordant findings to those previously published with the SP263 clone on smaller number of selected sarcomas \[[@pone.0222551.ref010], [@pone.0222551.ref018]\]. In this study, we demonstrated the highest expression of PD-L1 in UPS (31%), followed by angiosarcomas (29%), RMS (26%, predominantly pleomorphic subtype), MFS (18%), LMS (11%) and DD-LPS (10%). Sarcomas uniformly negative for PD-L1 expression in our series included ALT/WDL, myxoid liposarcomas, synovial sarcomas, pleomorphic liposarcomas, and Ewing sarcomas. This is in line with the previous observation that PD-L1 expression is a feature of sarcomas with a complex karyotype with or without high mutation burden \[[@pone.0222551.ref018]\] and only seen in our cases related to the complex karyotype group (UPS, angiosarcomas, pleomorphic RMS, MFS, LMS and DD-LPS). Our results however, differ when compared with other similar studies using antibodies other than the SP263 and variable cut-offs (i.e. \>2+ and \>5%\[[@pone.0222551.ref012]\]). In some of these series, the frequency of PD-L1 expression ranges from absent (0%) with the Abcam (ab58810 and ab205921) and SP142 clones \[[@pone.0222551.ref007], [@pone.0222551.ref008]\] to low (12%: H-130 clone)\[[@pone.0222551.ref009]\], intermediate (26--30%: AM2653AF-N. Acris & SP263)\[[@pone.0222551.ref010], [@pone.0222551.ref011]\] and high (58% & 65% with BD Pharmingen and R&D Systems and the H-130, Santa Cruz clones, respectively\[[@pone.0222551.ref012], [@pone.0222551.ref013]\]). Although strong correlation has been established for some clones (i.e. SP263 and 22C3) but less for others (SP142\[[@pone.0222551.ref018]\]), such comparative analyses have not been widely performed in sarcomas as opposed to lung adenocarcinomas. Our results are also discordant with studies reporting high PD-L1 expression in some specific sarcoma entities not identified in our cohort (i.e. liposarcomas\[[@pone.0222551.ref016]\], myxoid liposarcomas\[[@pone.0222551.ref012]\], synovial sarcomas\[[@pone.0222551.ref013]\] and Ewing's sarcoma family of tumours \[[@pone.0222551.ref013], [@pone.0222551.ref034]\].

We did not investigate the correlation between PD-L1 IHC expression and specific clinical pathological variables (i.e. tumour size, grade, site, patient's age, etc), as such correlation has not been previously identified \[[@pone.0222551.ref009], [@pone.0222551.ref014]\] and no obvious trend was seen in our cohort (See [Table 1](#pone.0222551.t001){ref-type="table"} for clinical pathological details shown for the Met/Rec cohort). In the largest meta-analysis published to date\[[@pone.0222551.ref014]\] including 1451 sarcoma patients, Zheng et al, suggested that PD-L1 expression does not correlate with patient age, histological grade, clinical stage, site, necrosis, chemotherapy, radiotherapy or incidence of metastasis or recurrence. This study also showed that PDL-L1 expression is a poor prognostic factor for event-free survival in both soft tissue sarcomas and osteosarcomas. A significant limitation of the Zheng et al's meta-analysis is that sarcoma subtypes were combined for statistical analysis, no taking into account the biological diversity of the different types of sarcomas. Therefore, large studies addressing the clinical diversity of soft tissue sarcomas stratified based on PD-L1 expression are lacking. In one of the aims of our study we confirmed that PD-L1 is differentially expressed according to sarcoma subtypes although we cannot address prognostic or predictive implications of its expression as clinical follow-up is not available.

With regards to increase / gain of PD-L1 in the metastatic setting, limited studies have documented similar findings in different tumour types. Lussier et al, in a study of 11 paediatric osteosarcomas, demonstrated that 75% of metastatic deposits but no primary osteosarcomas expressed PD-L1\[[@pone.0222551.ref035]\]. The same phenomenon was observed in a case of dedifferentiated chondrosarcoma, which showed absence of PD-L1 in the primary tumour and positive expression in the metastasis\[[@pone.0222551.ref036]\] and this has also recently been documented in a series of metastatic renal cell carcinomas\[[@pone.0222551.ref037]\]. Here, we report for the first time that gain in PD-L1 protein expression can occur in the context of metastatic/recurrent myxofibrosarcoma, leiomyosarcoma and pleomorphic rhabdomyosarcoma. We demonstrated on full section analysis that the percentage of positive cells expressing PD-L1 increased in the metastatic/recurrent site compared to the primary tumour in a total of 6 of 9 cases with a particularly marked increase in 3 of those cases. Based on results of the KENOTE-010 study, patients with high PD-L1 score (\>50%) have significantly increased benefit with pembrolizumab compared to those with \>1%\[[@pone.0222551.ref003]\]. Therefore, it is possible that these patients, all of which showed \>50% positive cells in the metastasis/recurrence but not in the primary tumour, may have an objective treatment response. Contrary to these findings, the few comparative similar analyses between paired primary and metastatic lung carcinoma samples have identified that discrepant PD-L1 expression, when it occurs, is due to negative expression in the metastatic deposit/s compared to primary tumours \[[@pone.0222551.ref008], [@pone.0222551.ref027], [@pone.0222551.ref038], [@pone.0222551.ref039]\]. It should be noted that in some of these studies, biopsies rather than resections have been used to determine concordance and intra-tumour heterogeneity for PD-L1 has been shown to account for the apparent discordance in some of those series.

With regards to our analysis of TILs assessed on H&E sections in a subset of cases, we identified no correlation with PD-L1 expression in the Met/Rec cohort but a significant association was identified for a specific sarcoma subset, leiomyosarcomas (n = 116, full subset). None of the three cases of the Met/Rec cohort with significant increase in the percentage of PD-L1 positive cells contained TILs. In fact, one of those cases had high TILs in the primary and absence in the brain metastasis ([Fig 3I, 3J, 3K and 3L](#pone.0222551.g003){ref-type="fig"}). Lack of TILs in brain metastases has been previously reported\[[@pone.0222551.ref038]\]. Our other Rec/Met paired cases showed concordant absence of TILs at initial presentation and on the metastasis / recurrence ([Table 1](#pone.0222551.t001){ref-type="table"}). As high density TILs (specifically, CD3+/CD8+) is an independent positive prognostic factor for OS and DFS in sarcomas\[[@pone.0222551.ref010]\], it would be expected that absence of TILs would correlate with aggressive behaviour in those sarcomas prone to recur and/or metastasise. Induction or oncogeneic activation of PD-L1 in non 'inflamed' tumours occurs through alternative pathways such as loss of PTEN or copy gain / amplification of CD274/PDL1 locus (Ch 9p24.1)\[[@pone.0222551.ref010], [@pone.0222551.ref015]\]. In our full cohort of leiomyosarcomas (n = 116), PD-L1 expression strongly correlated with the presence of moderate-to-high TILs identified on H&E sections when compared to absent-to-minimal (\<10%) TILs (\<0.0001, Fisher's exact test). In a recent series of uterine smooth muscle tumours including 23 LMSs \[[@pone.0222551.ref040]\], Shane et al, demonstrated higher CD3+ TILs in leiomyosarcomas but direct correlation with co-expression of PD-L1 was not assessed\[[@pone.0222551.ref040]\].

We did not characterise subsets of TILs (ie.. CD8+, FoXP3+, etc) because this has been previously published\[[@pone.0222551.ref005], [@pone.0222551.ref007]--[@pone.0222551.ref019]\] and because our study focused on the possible relevance of TILs on histological H&E-stained sections. With regards to the correlation between PD-L1 and PD-1 expression this is conflicting with a study from the Cancer Genome Atlas Research Network demonstrating that PD-L1 mRNA does not correlate with PD-1\[[@pone.0222551.ref021]\]. This has also been documented in smaller studies \[[@pone.0222551.ref007]\].

Our study has a number of limitations. First of all, it is essential to emphasise that the clinical predictive value of PD-L1 protein expression assessed on tumour samples has not been widely investigated in sarcoma patients and there is currently only scanty evidence from single-arm phase 2 studies of response to PD-L1 inhibitors. Importantly, in the SARC028 trial clinical, response to checkpoint inhibitors was seen in cases even in the absence of PD-L1 expression \[[@pone.0222551.ref005]\], which may indicate that PD-L1 expression may not necessarily impact treatment response. Nonetheless, 2 of the 3 patients with positive PD-L1 expression in that trial (4% in total; 3 of 70 patients with a range of sarcoma types) showed either complete or partial treatment response. This is suggestive of some predictive value of PD-L1 expression assessed in pre-treatment biopsies \[[@pone.0222551.ref005]\]. PD-L1 expression on our full cohort was assessed using TMAs. This was partly overcome by performing PD-L1 IHC and assessment of TILs on full sections. There is no clinical follow-up available for our cases including a lack of details about treatment modality in the vast majority. Importantly, the cohort predominantly includes treatment-naïve sarcomas with the exception for the Met/Rec cohort. For this subset of cases, it is expected that patients were treated with conventional regimens according to sarcoma type. Hence, it is likely that they were treated following universal guidelines before clinical trials were more widely available and according to clinical stage. This would make comparative analyses reliable. Although radiotherapy has been shown to induce PD-L1 expression\[[@pone.0222551.ref033]\], our cases with documented post-radiotherapy ([Table 1](#pone.0222551.t001){ref-type="table"}; n = 5) showed \<10% PD-L1 expression. Finally, the size of the metastatic/recurrent cohort is limited and therefore, a larger number of paired samples is needed to further validate these findings. Nonetheless, paired samples are scant in most centres but comprise very valuable resource to understand the biology of sarcoma progression.

Conclusions {#sec008}
===========

Overall, we conclude that the frequency of PD-L1 expression in sarcomas is limited to some sarcoma subtypes and that variable selection of clones and cut-offs contributes to the marked discrepancy across different series. We focused on the SP263 companion kit as this selectively identifies patient's eligibility to anti-PD-1 and/ PD-L1 inhibitors in lung and urothelial carcinoma. Our study showed that PD-L1 can objectively increase in a small proportion of cases in paired metastases/recurrent disease to \>50% expression of the tumour cells. This suggests the possibility of treatment response to immune checkpoint inhibitors in the metastatic/recurrent setting but unlikely in the primary tumour in a proportion of cases (i.e. as PD-L1 of 1--5%). In our assessment of TILs on H&E sections, we demonstrated that PD-L1 expression in leiomyosarcomas was associated with at least moderate levels of TILs identified on H&E sections. Although the prognostic significance of this association cannot be elucidated in this study, in view of the lack of clinical follow-up, the positive correlation of TILs and PD-L1 may help to triage the LMS cases which may benefit from PD-L1 IHC. Our results indicate that LMSs with moderate TILs are significantly more likely to harbour PD-L1 expression.
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